IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Hamps Bio IPO is a Fixed Price listing on BSE SME exchange. The company is based in Bharuch and caters to Pharmaceutical sector. Marwadi Chandarana Intermediaries Brokers is the merchant banker of Hamps Bio IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 29th July 2024.
Hamps Bio IPO posted revenues of ₹ 7.47 crores and PAT of ₹ 0.58 crores in FY25 on annualised basis.
Revenue:
₹ 7.30 Cr.
EBITDA Margin:
15.26
% 
Net Worth: ₹ 3.70 Cr.
Market Capitalisation:
₹ 22.22 Cr.
P/E:
38.03 times
P/BV: 2.24 times
EV/EBITDA: 21.09 times
Financial results of Hamps Bio IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Oct-24 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 6.44 | 5.14 | 3.95 | 3.64 | |
| Net Worth | 3.70 | 3.37 | 1.36 | 1.00 | |
| Total Debt | 1.38 | 1.04 | 1.73 | 2.04 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
4.26
7.30 |
6.47 | 5.57 | 5.34 | |
EBITDA
EBITDA on annualised basis |
0.65
1.11 |
1.17 | 0.86 | 0.61 | |
PAT
PAT on annualised basis |
0.34
0.58 |
0.50 | 0.35 | 0.12 | |
Hamps Bio IPO PAT Margin is 7.98 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Hamps Bio IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Oct-24 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| EBITDA Margin (%) | 15.26 | 18.08 | 15.44 | 11.42 |
| PAT Margin (%) | 7.98 | 7.73 | 6.28 | 2.25 |
| EPS (₹) | 1.09 | 1.76 | 1.50 | 0.51 |
| ROE (%) | 9.19 | 14.84 | 25.74 | 12.00 |
| ROCE (%) | [●] | [●] | [●] | [●] |
| ROA (%) | 5.28 | 9.73 | 8.86 | 3.30 |
| Debt to Equity | 0.37 | 0.31 | 1.27 | 2.04 |
The market Capitalisation of Hamps Bio IPO is ₹ 22.22 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Hamps Bio IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Hamps Bio IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Hamps Bio IPO is ₹ 22.22 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Hamps Bio IPO has a Price-to-Earnings (PE) ratio of 38.03 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Hamps Bio IPO reported revenue of ₹ 7.47 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Hamps Bio IPO provide insights into sales growth, market demand, and business scalability.
Hamps Bio recorded an EBITDA of ₹ 1.11 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Hamps Bio Profit After Tax (PAT) is ₹ 0.58 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 7.30 Cr.
EBITDA Margin:
15.26
%
Net Worth: ₹ 3.70 Cr.
Market Capitalisation:
₹ 22.22 Cr.
P/E:
38.03 times
P/BV: 2.24 times
EV/EBITDA: 21.09 times
Hamps Bio operates in Pharmaceutical and Distribution Of Pharma Formulations And Manufacturing Of Freeze Dried And Frozen Foods. The Issue is listed on BSE SME in Dec, 2024. Hamps Bio IPO size was 6.22 with Issue price of 51.00 .
Merchant Banker(s) of Hamps Bio IPO: Marwadi Chandarana Intermediaries Brokers Private Limited
Hamps Bio IPO subscription was 1057.00 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Hamps Bio IPO listed at a listing price of 101.74 against the offer price of 51.00.
The current market price of Hamps Bio is 43.00.
Why Us?
